Kura Oncology Announces Senior Executive Promotions
Kura Oncology, Inc. (NASDAQ: KURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting [Yahoo! Finance]
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
Kura Oncology to Host Virtual Investor Event on December 9, 2024 [Yahoo! Finance]